[go: up one dir, main page]

DK1093370T3 - Farmaceutisk præparat til behandling af diabetes - Google Patents

Farmaceutisk præparat til behandling af diabetes

Info

Publication number
DK1093370T3
DK1093370T3 DK99957622T DK99957622T DK1093370T3 DK 1093370 T3 DK1093370 T3 DK 1093370T3 DK 99957622 T DK99957622 T DK 99957622T DK 99957622 T DK99957622 T DK 99957622T DK 1093370 T3 DK1093370 T3 DK 1093370T3
Authority
DK
Denmark
Prior art keywords
diabetes
treatment
pharmaceutical preparation
pharmaceutical
preparation
Prior art date
Application number
DK99957622T
Other languages
English (en)
Inventor
Hiroyuki Odaka
Masahiro Yamane
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of DK1093370T3 publication Critical patent/DK1093370T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK99957622T 1998-06-30 1999-06-29 Farmaceutisk præparat til behandling af diabetes DK1093370T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP18370098 1998-06-30

Publications (1)

Publication Number Publication Date
DK1093370T3 true DK1093370T3 (da) 2006-05-22

Family

ID=16140426

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99957622T DK1093370T3 (da) 1998-06-30 1999-06-29 Farmaceutisk præparat til behandling af diabetes

Country Status (16)

Country Link
US (2) US6329403B1 (da)
EP (1) EP1093370B1 (da)
KR (1) KR20010043455A (da)
CN (1) CN1305376A (da)
AR (1) AR019727A1 (da)
AT (1) ATE318138T1 (da)
AU (1) AU754740B2 (da)
BR (1) BR9911656A (da)
CA (1) CA2329004C (da)
DE (1) DE69929996T2 (da)
DK (1) DK1093370T3 (da)
ES (1) ES2255316T3 (da)
ID (1) ID27415A (da)
NO (1) NO20006630L (da)
WO (1) WO2000000195A1 (da)
ZA (1) ZA200006262B (da)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607751B1 (en) * 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
TWI249401B (en) * 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
DK1133312T3 (da) 1999-06-21 2008-01-02 Lilly Co Eli Synergistisk anvendelse af thiazolidindioner med glucagonlignende peptid-1 og agonister deraf til behandling af ikke-insulinafhængig diabetes
AT409081B (de) * 2000-02-16 2002-05-27 Gebro Pharma Gmbh Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
EP1295609A4 (en) * 2000-02-24 2004-11-03 Takeda Chemical Industries Ltd MEDICINES WITH MIXED ACTIVE SUBSTANCES
GB0021978D0 (en) * 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
JP2004331500A (ja) * 2001-02-16 2004-11-25 Dainippon Pharmaceut Co Ltd 血中濃度制御製剤
CA2439063A1 (en) * 2001-03-12 2002-09-19 Novartis Ag Combination of nateglinide or repaglinide with at least one further antidiabetic compound
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
US20030008838A1 (en) * 2001-04-03 2003-01-09 Havel Peter J. Method of increasing endogenous leptin production
US20070203225A1 (en) * 2001-04-03 2007-08-30 Havel Peter J Method of increasing endogenous adiponectin production and leptin production
JP2002360666A (ja) * 2001-06-11 2002-12-17 Takeda Chem Ind Ltd コバルト合金を用いた打錠用杵臼
WO2003059378A2 (en) 2001-12-29 2003-07-24 Novo Nordisk A/S Combined use of a glp-1 compound and another drug for treating dyslipidemia
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
US7101845B2 (en) * 2002-01-31 2006-09-05 Joslin Diabetes Center, Inc. Methods of modulating β cell function
AU2002356419A1 (en) 2002-06-17 2003-12-31 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
EP1388352A1 (en) * 2002-08-08 2004-02-11 Laboratoires Fournier S.A. Use of a ppar-alpha agonist to treat patients suffering from weight gain associated with a ppar-gamma agonist treatment
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
WO2004078716A1 (en) * 2003-03-03 2004-09-16 Merck & Co. Inc. Acylated piperazine derivatives as melanocortin-4 receptor agonists
US20050187266A1 (en) * 2003-04-15 2005-08-25 Pfizer Inc Alpha substituted carboxylic acids
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US7008957B2 (en) * 2003-07-25 2006-03-07 Sanofi-Aventis Deutschland Gmbh Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
US7264813B2 (en) 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
MXPA06005343A (es) * 2003-11-14 2006-07-10 Vertex Pharma Tiazoles y oxazoles utiles como moduladores de transportadores con cassette de union a atp.
EP1727559A1 (en) * 2004-01-26 2006-12-06 Eli Lilly And Company Use of fgf-21 and a thiazolidinedione for treating type 2 diabetes
AR047541A1 (es) * 2004-02-13 2006-01-25 Sandoz Ag Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
EP1730310A2 (en) * 2004-03-22 2006-12-13 The Regents Of The University Of California A formulation for increasing endogenous adiponectin and leptin production
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20060024361A1 (en) * 2004-07-28 2006-02-02 Isa Odidi Disintegrant assisted controlled release technology
US10624858B2 (en) * 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
DE112005002969B4 (de) * 2004-12-03 2016-09-22 Vetco Gray Scandinavia As Hybridsteuerungssystem und -verfahren
KR100697982B1 (ko) * 2005-07-08 2007-03-23 대봉엘에스 주식회사 로시글리타존의 제조방법
KR100697983B1 (ko) * 2005-07-08 2007-03-23 대봉엘에스 주식회사 신규 중간체 및 이를 이용한 피오글리타존의 제조방법
US20070129444A1 (en) * 2005-12-06 2007-06-07 Mallinckrodt Inc. Novel weight reduction composition and uses thereof
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CN101453993A (zh) 2006-04-03 2009-06-10 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
EP2016076A2 (en) * 2007-01-22 2009-01-21 Teva Pharmaceutical Industries Ltd. Polymorphic forms of rosiglitazone hydrobromide and processes for preparation thereof
EP2561870A1 (en) * 2007-03-30 2013-02-27 Tioga Pharmaceuticals, Inc. Kappa-Opiate Agonists For The Treatment Of Diarrhea-Predominant and Alternating Irritable Bowel Syndrome
US20090318520A1 (en) 2008-06-20 2009-12-24 Afecta Pharmaceuticals Drive Use of isoindoles for the treatment of neurobehavioral disorders
JP5894174B2 (ja) * 2010-11-03 2016-03-23 アレコー リミテッド グルカゴンを含む新規組成物
WO2014072363A1 (en) * 2012-11-06 2014-05-15 Nanologica Ab A porous silica material for use as a pharmaceutical or dietary active ingredient
US20170056352A1 (en) 2015-08-25 2017-03-02 Rgenix, Inc. PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
WO2018160178A1 (en) 2017-03-01 2018-09-07 Rgenix, Inc. Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof
CA3161341A1 (en) 2019-12-11 2021-06-17 Masoud Fakhr Tavazoie Methods of treating cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2030174C (en) 1990-01-10 1996-12-24 Anthony H. Cincotta Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hypoglycemia in vertebrates
GB9111426D0 (en) * 1991-05-28 1991-07-17 Ici Plc Chemical compounds
EP0601001B1 (en) * 1991-08-26 1997-04-16 PHARMACIA & UPJOHN COMPANY Liquid food product containing 3-guanidinopropionic acid
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
JP2000504021A (ja) * 1996-02-02 2000-04-04 メルク エンド カンパニー インコーポレーテッド 糖尿病及び関連疾患状態を治療する方法
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process

Also Published As

Publication number Publication date
WO2000000195A1 (en) 2000-01-06
US6329403B1 (en) 2001-12-11
EP1093370A1 (en) 2001-04-25
ES2255316T3 (es) 2006-06-16
US20020086885A1 (en) 2002-07-04
BR9911656A (pt) 2001-03-20
ID27415A (id) 2001-04-05
AU4291499A (en) 2000-01-17
NO20006630D0 (no) 2000-12-22
AR019727A1 (es) 2002-03-13
EP1093370B1 (en) 2006-02-22
ZA200006262B (en) 2001-11-02
DE69929996T2 (de) 2006-11-16
DE69929996D1 (de) 2006-04-27
CA2329004A1 (en) 2000-01-06
NO20006630L (no) 2001-02-26
KR20010043455A (ko) 2001-05-25
AU754740B2 (en) 2002-11-21
CA2329004C (en) 2009-04-14
ATE318138T1 (de) 2006-03-15
CN1305376A (zh) 2001-07-25

Similar Documents

Publication Publication Date Title
DK1093370T3 (da) Farmaceutisk præparat til behandling af diabetes
DK0941103T3 (da) Farmaceutisk præparat til behandling af diabetes
DK1196163T3 (da) Farmaceutiske sammensætninger til behandling af insulinresistens
DK1158992T3 (da) Anvendelse af xenon til fremstilling af et farmaceutisk præparat til behandling af neurointoksikationer
DK1147083T3 (da) Arylpiperazinyl-cyclohexylindolderivater til behandling af depression
DK1275387T3 (da) Fremgangsmåde til fremstilling af farmaceutiske præparater af fenofibrat med höj biologisk tilgængelighed
DK1144395T3 (da) 2-amino-benzoxazinon-derivater til behandling af fedme
DK2412368T3 (da) Sammensætning til behandling af ar
DK1196172T3 (da) (S,S)-reboxetin til behandling af kronisk smerte
NO20022087D0 (no) Fremgangsmåte for behandling av diabetes
DK0956858T3 (da) Farmaceutiske præparater indeholdende lactobacilli til behandling af vaginale infektioner
PT1066027E (pt) Composicao farmaceutica de topiramato
DK1173431T3 (da) Fremgangsmåde til fremstilling af citalopram
DK1105382T3 (da) Fremgangsmåde til fremstilling af citalopram
DK1159274T3 (da) Fremgangsmåde til fremstilling af citalopram
DK1063990T3 (da) Anvendelse af Biochanin-beriget ekstrakt til behandling af östrogen-associerede lidelser
DK1165576T3 (da) Fremgangsmåde til fremstilling af amin-platin-komplekser
DK1466615T3 (da) Farmaceutisk præparat
DK1282616T3 (da) Hydroxyphenylpiperidin-4-ylidenmethylbenzamidderivater til behandling af smerter
DK1150991T3 (da) Præparater til behandling af inflammatoriske reaktioner
NO20005179D0 (no) Medikament behandling
DK0979079T3 (da) Anvendelse af tetrahydropyridinderivater til fremstilling af lægemidler til behandling af sygdomme, der medförer en demyelinisering
PT1154777E (pt) Medicamento para o tratamento de hipertensao arterial
DK199800837A (da) Anlæg til behandling af emner
NO20014926L (no) Farmasöytiske forbindelser